Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Letter presents interim safety analysis from Com-COV study, which found increase in systemic reactogenicity after boost dose reported by participants in heterologous vaccine schedules (VSs) in comparison to homologous VSs, and this was accompanied by increased paracetamol usage.

Source:

The Lancet